SynthesisInfection2026
Efficacy and safety of imipenem-cilastatin-relebactam in resistant infections: a systematic review and meta-analysis of randomized controlled trials.
Synthesis in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntimicrobial resistance represents a major global health concern, particularly with the rise of carbapenem-resistant pathogens that significantly constrain therapeutic options. Imipenem-cilastatin-relebactam (IMI-REL), a novel combination of a β-lactam and β-lactamase inhibitor, has emerged as a promising treatment for patients with few alternatives. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of IMI-REL in comparison with standard-of-care antibiotics for managing resistant or complicated bacterial infections.
methodsA systematic review and meta-analysis of randomized controlled trials (RCTs) was performed following PRISMA guidelines. Comprehensive searches of PubMed, Scopus, and Web of Science were conducted up to July 2025. Eligible studies included RCTs comparing IMI-REL with alternative antibiotics in patients with resistant or complicated infections, reporting clinical and/or microbiological outcomes. The primary outcomes were clinical and microbiological responses assessed at the end of intravenous therapy (DCIV), early follow-up (EFU), and late follow-up (LFU). Secondary outcomes comprised adverse events, serious adverse events (SAEs), treatment discontinuation due to adverse events, and all-cause mortality.
resultsSix randomized controlled trials were included, encompassing different types of infections caused by imipenem-resistant pathogens. Across these studies, IMI-REL demonstrated comparable clinical responses to standard-of-care regimens at the end of intravenous therapy (DCIV) (RR: 1.04; 95% CI 0.94-1.16), early follow-up (EFU) (RR: 1.02; 95% CI 0.92-1.12), and late follow-up (LFU) (RR: 1.01; 95% CI 0.91-1.12). Microbiological outcomes were similarly equivalent between treatment groups. Safety analyses indicated no increased risk of adverse events (RR: 1.01; 95% CI 0.77-1.32), serious adverse events (SAEs) (RR: 0.93; 95% CI 0.70-1.23), discontinuation due to adverse events (RR: 0.62; 95% CI 0.39-1.01), or mortality (RR: 0.83; 95% CI 0.41-1.67).
conclusionIMI-REL demonstrates efficacy and safety comparable to standard-of-care treatments for resistant and complicated infections. It may serve as a valuable therapeutic option for patients with limited alternatives and can support antimicrobial stewardship when administered as a short-course empirical therapy followed by appropriate de-escalation.
Indexed as
Identifiers
42012579What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.